Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Magenta Therapeutics

Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Magenta Therapeutics Appoints David Nichols as Chief Technical Officer
From Magenta Therapeutics
Via Business Wire
Tickers MGTA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.